Association between Polygenic Risk Score and One-Year Outcomes Following As-Needed Aflibercept Therapy for Exudative Age-Related Macular Degeneration

Association between Polygenic Risk Score and One-Year Outcomes Following As-Needed Aflibercept Therapy for Exudative Age-Related Macular Degeneration

We investigated whether polygenic risk score (PRS) was associated with one-year outcome of as-needed aflibercept therapy for exudative age-related macular degeneration (AMD), including AMD (<i>n</i> = 129) and polypoidal choroidal vasculopathy (<i>n</i> = 132). A total of 261...

Full description

Bibliographic Details
Main Authors: Taiyo Shijo, Yoichi Sakurada, Seigo Yoneyama, Wataru Kikushima, Atsushi Sugiyama, Mio Matsubara, Yoshiko Fukuda, Fumihiko Mabuchi, Kenji Kashiwagi
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Pharmaceuticals
Subjects:
age-related macular degeneration
polygenic risk score
aflibercept therapy
treatment outcomes
<i>ARMS2</i>
<i>CFH</i>
Online Access:https://www.mdpi.com/1424-8247/13/9/257

Internet

https://www.mdpi.com/1424-8247/13/9/257

Similar Items